Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced new data on the use of TEPEZZA (teprotumumab-trbw) in patients with dysthyroid optic neuropathy (DON) at NANOS 2023.